|Back Zoom + Zoom - Block Traded|
CSPC PHARMA 'Epirubicin Hydrochloride Liposome Injection' Approved for Clinical Trials in China
CSPC PHARMA (01093.HK) announced that “Epirubicin Hydrochloride Liposome Injection” developed by CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.*, a subsidiary of the Company, was granted approval by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.
AAStocks Financial News
Web Site: www.aastocks.com